Today’s Top Stock Idea – Check It Out! 📊

One of this year’s must-watch stocks…                                                                                                                                                                                                                                                                                                                                                                                                                 July 23, 2024 | [Read Online]( Today’s Top Stock Idea – Check It Out! 📊 Real-time trading, streaming charts, market analysis and penny stock scanners. Yeah, that’s right and it’s available to you RIGHT NOW - free!  Market Master’s trading room, where our top traders share market insight and live trade ideas daily. [Jump in right here and take a look for yourself!]( GM, Jeff here! As I pointed out in last night’s email, the markets (especially the IWM) are signaling a very bullish “Gamma Trigger” setup to me right now. I don’t necessarily think this is a new long-term buy signal, but for the next few days, I think this will be a very strong market. I was able to cash in on this signal yesterday, along with my Bullseye Trades members, with an excellent trade idea on IWM calls, which enabled me to capture a big profit. Today, I am hoping to land on another winning idea with a biotech stock I have been following for quite a while now. I originally brought this idea to your attention in March, and it has gone on a wild run since then, reaching over $10 at one point. Today, I think it is an excellent time to revisit this one, as it has an amazing setup once again. Go to your favorite platform and pull up Actinium Pharmaceuticals, Inc. (ATNM) right now, and I’ll show you what I see. In the price chart below, you’ll see the year-to-date action for ATNM. First of all, note the trend. It is clearly under accumulation and has been building a series of higher lows all year long (that’s the simple definition of an uptrend!)  That is extremely bullish, if you ask me. ATNM is also up over 40% so far this year, which is nearly TRIPLE the return you have seen from the SPY. Right now, the stock is at what I think is a key support level. You never know what will happen in the future, but looking at how sharp ATNM's rebounds have been this year, I think it really deserves your attention right now. This is a very powerful pattern for an obviously strong stock. We could be sitting on the cusp of something big today. One of my favorite sites for looking at overall metrics for a stock is TipRanks.  If you [look at that site right now](, you’ll see there is a “perfect 10” for their Smart Score on ATNM. This score is derived from a combination of factors, and it shows how much confidence they have in overall strength right now. One of the biggest factors is how analysts view the stock, and you won’t find many stocks with price targets like ATNM has. [You can see]( that analysts who cover ATNM have an average price target over 300% higher than current levels. This is clearly a stock that has the attention of the market right now. With all of these catalysts, I think we could see another big move for ATNM at any moment.  You need to make sure ATNM is on your radar this morning. As you do your homework on this stock, here are some points I think are important on it… Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing targeted radiation treatments for cancer. The company has a big portfolio of intellectual property, with more than 220 patents and patent applications worldwide. At the core of its strategy is a nuclear isotope called Actinium-225, which the company [describes]( as “the most powerful medical grade radioisotope known to man.” Critically, “its power is emitted over a short distance of a few millimeters, making it ideal for targeted radiotherapy.” The company’s therapies deploy this weapon directly to cancer cells using what it amusingly calls Antibody Warhead Enabling (AWE) technology. The idea is to target cancer cells specifically, like a heat-seeking missile, unlike prevailing radiation therapies which have a much more systemic impact. This strategy has possible indications for many kinds of cancers, but ATNM put it fully to the test in a recently completed Phase III trial for older patients with relapsed or refractory acute myeloid leukemia (AML). The results were incredible… In the control arm of the trial, no patients survived beyond one year, despite receiving the usual treatments. For the patients who received Iomab-B — one of the company’s proprietary radiopharmaceuticals — 20.1% survived one year, and 11.5% were alive after two years, a duration the company [says]( is “highly indicative of long-term outcomes including potential cure.” A two-year survival rate of 11.5% may not seem great, but this is a particularly nasty form of cancer, so this therapy has the potential to become the new standard of care in these patients. It’s because of Iomab-B’s potential to fill an unmet medical need that the FDA granted it an [orphan drug designation]( in 2016. Eight years later, that tree is bearing fruit. ATNM intends to file a Biologics License Application (BLA) with the FDA for Iomab-B later this year, setting the stage for commercialization. While this could undoubtedly be a boon for the company, in my view the success of the Iomab-B trial is best seen as a proof-of-concept for the company’s targeted radiotherapies… And indeed, ATNM has a much broader [product pipeline]( and says its therapies could apply to solid tumors in addition to blood cancers. In March, for instance, the company [announced]( a clinical trial to study Iomab-ACT — which you can read more about [here]( — with a leading FDA approved CAR-T cell therapy at the University of Texas Southwestern (UTSW). And last month, ATNM [announced]( the results of a Phase 1b combination trial that included “Actimab-A,” which you can read more about [here](. The trial featured patients with a very high risk profile, but still it “produced high rates of response and measurable residual disease negativity and improved survival outcomes across all patient subsets.” As of February, the company [said]( that its ~$83.0 million cash is projected to fund operations through 2025. Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration. Bottom line: This stock is one of the hottest stories of the year. The sector is one of the most exciting to watch right now, and ATNM is a clear leader to focus on. Make sure ATNM is on the top of your watchlist right now. To Your Success, Jeff Bishop P.S. Make sure you join me and over 1000 traders in the [Market Master’s trading room]( today for live trading signals and education. You can access it at no cost right now. Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.” Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received thirty thousand dollars (cash) from Sica Media for advertising Actinium Pharmaceuticals, Inc for a one day marketing program on July 23, 2024. We previously received seventeen thousand five hundred dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising Actinium Pharmaceuticals, Inc from a period beginning on for a one day marketing program on March 18, 2024. These amounts were paid by someone else not connected to Actinium Pharmaceuticals, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. Now, diving right into Actinium Pharmaceuticals, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now. Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at . FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers mentioned in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. If you have a current active subscription with Jason Bond Picks you will need to contact us here if you want to cancel your subscription. Opting out of emails does not remove you from your service at JasonBondPicks.com. Update your email preferences or unsubscribe [here]( © 2024 Jason Bond Picks 62 Calef Hwy. #233 Lee, NH 03861, United States of America [Terms of Service](